Navigation Links
New medical weapons to protect against anthrax attacks

The 2001 anthrax attacks in the United States are fostering development of a new generation of vaccines, antibiotics, and other medications to protect people against the potentially deadly bacteria in any future bioterrorist incident. That's the conclusion of a sweeping overview of scientific research on medical technology to combat the anthrax threat. It appears in ACS' bi-weekly Journal of Medicinal Chemistry.

In the article, Dimitrios Bouzianas notes that several existing antibiotics are available to combat an anthrax infection. However, the emergence of artificially engineered B. anthracis strains, resistant to multiple antibiotics (including the front-line agents ciprofloxacin, doxycycline, and β-lactam antibiotics) has prompted researchers to pursue additional therapeutic options. Such alternatives include small molecules and antibodies against toxins that the lethal bacteria secrete. Passive immunization using a polyclonal or a high-affinity monoclonal antibody may offer adjunctive value to antibiotic therapy. Today's drug arsenal has another weakness: no medications available to fight the dangerous toxin that can circulate in a person's blood when antibiotic treatment begins after the disease has taken hold. Therefore, there is an urgent need for the discovery of antitoxin agents that would be effective at the end stage of anthrax.

Bouzianas describes promising new treatments now in various stages of development. They include a new genre of anthrax vaccines that would be more effective and yet require fewer doses than current vaccines. Among them: A long-sought inhalable vaccine that people might self-administer without a needle. Importantly, this powered vaccine would not require refrigeration and would have a long shelf life ideal for the strategic drug stockpiles kept on hand for rapid distribution in case of national emergencies. Also on the horizon: New antibiotics that are less likely to encounter resistance and medicines that can block the effects of anthrax toxin. Because anthrax is rare as a natural disease in humans, the development of new treatment modalities is seriously hampered by the difficulty in demonstrating their effectiveness in humans.


Contact: Michael Bernstein
American Chemical Society

Related biology news :

1. American College of Medical Genetics responds to new FDA labeling decision for warfarin
2. M2SYS Partners With Gnosis Medical Services to Provide Accurate Patient Identification in Developing Countries Through Innovative Biometrics Solution
3. Boston University biomedical engineers find chink in bacterias armor
4. $22 million gift from Alfred Taubman launches new biomedical research institute
5. USC biomedical team to participate in $6 million low vision project
6. 3 Columbia University Medical Center faculty elected to Institute of Medicine
7. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
8. UMass Medical School researchers receive $8.5M grant award to fight AIDS
9. Natural product discovery by Cleveland medical researchers blocks tissue destruction
10. Triage study challenges notions of emergency medical response to disaster
11. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
Post Your Comments:
Related Image:
New medical weapons to protect against anthrax attacks
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... ) The integration ... security to access and transact across channels. Using ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a range ... place between the two entities said Poloz. Speaking ... Ottawa , he pointed to the country,s inflation ... federal government. "In ... "Both institutions have common economic goals, why not sit down ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
Breaking Biology Technology: